scispace - formally typeset
Journal ArticleDOI

A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study.

Reads0
Chats0
TLDR
Regular HD using the MCO dialyzer did not result in a significant fall in serum albumin and there was no improvement in restless legs symptoms, quality of life, 6MWT or MIS scores.
Abstract
Background: A new class of dialysis membrane, the mid cut-off (MCO) dialyzer, has been developed to improve the clearance of uremic toxins in hemodialysis (HD). The a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HemoDialysis patients (REMOVAL-HD) study aimed to determine if regular use of MCO dialyzer was safe and specifically did not result in a significant loss of albumin. Methods: This investigator initiated, crossover, longitudinal, device study was conducted across 9 centers in Australia and New Zealand (n = 89). Participants had a 4-week wash-in with high-flux HD, followed by 24-week intervention with MCO HD and a subsequent 4-week wash-out with high-flux HD. The primary outcome was change in serum albumin between weeks 4 and 28. Secondary outcomes included trends in serum albumin, changes in kappa- and lambda-free light chains (FLC), 6-min walk test (6MWT), malnutrition inflammation score (MIS), restless legs score and quality of life. Results: Participants had a mean age of 66 ± 14 years, 62% were men, 45% were anuric, and 51% had ­diabetes. There was no reduction in serum albumin following treatment with MCO HD (mean reduction –0.7 g/L, 95% CI –1.5 to 0.1). A sustained, unexplained reduction in serum albumin (>25%) was not observed in any participant. A reduction in FLC was observed 2 weeks into MCO HD (lambda-FLC: Δ –9.1 mg/L, 95% CI –14.4 to –3.7; kappa-FLC: Δ –5.7 mg/L, 95% CI –9.8 to –1.6) and was sustained for the rest of the study intervention. Both FLC increased after the cessation of MCO use. There was no improvement in restless legs symptoms, quality of life, 6MWT or MIS scores. Conclusions: Regular HD using the MCO dialyzer did not result in a significant fall in serum albumin. There were no effects on quality of life, functional status or nutrition. Trial Registration: Australian New Zealand Clinical Trials Registry Number (ANZCTRN) 12616000804482.

read more

Citations
More filters
Journal ArticleDOI

Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial.

TL;DR: Hemodialysis therapy with the Theranova 400 Dialyzer provides superior removal of larger middle molecules, as exemplified by free λ light chains, compared with a similar size high-flux dialyzer, while maintaining serum albumin levels after 24 weeks of treatment.
Journal ArticleDOI

Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis.

TL;DR: In this article, the impact of dialyzer selection on albumin losses during conventional hemodialysis, including the clinical relevance of such losses on serum albumin levels, is examined.
Journal ArticleDOI

High-volume online haemodiafiltration treatment and outcome of end-stage renal disease patients: more than one mode

TL;DR: Ongoing and future trials should provide definitive proof for the superiority of high-volume OL-HDF over conventional HD or HDx to give guidance for the most favourable mode of dialytic therapy for clinical use.
Journal ArticleDOI

Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins

TL;DR: In this article, the authors proposed to target uremic toxins and/or their pathways, which may decrease the risk of cardiovascular disease in CKD patients and improve quality of life, morbidity and mortality.
References
More filters
Journal ArticleDOI

The Quality of Life of Patients with End-Stage Renal Disease

TL;DR: The quality of life of transplant recipients compared well with that of the general population, but despite favorable subjective assessments, patients undergoing dialysis did not work or function at the same level as people in the generalpopulation.
Journal ArticleDOI

A Malnutrition-Inflammation Score is correlated with morbidity and mortality in maintenance hemodialysis patients

TL;DR: The MIS appears to be a comprehensive scoring system with significant associations with prospective hospitalization and mortality, as well as measures of nutrition, inflammation, and anemia in MHD patients, and may be superior to the conventional SGA and the DMS as a predictor of dialysis outcome and an indicator of MICS.
Journal ArticleDOI

Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS

TL;DR: This study confirms that several readily-measured nutritional indicators predict mortality among hemodialysis patients and that changes in indicator values over six months provide additional important prognostic information.
Journal ArticleDOI

A Multicenter Study Comparing Two Numerical Versions of the Edmonton Symptom Assessment System in Palliative Care Patients

TL;DR: The ESAS-r retains core elements of the ESAS, with improved interpretation and clarity of symptom intensity assessment, and represents the next generation of ESAS development, with further validation recommended for drowsiness, appetite, and well-being.
Related Papers (5)